Also, in agreement with previous reports (Mavaddat et al., 2012), we detected most BRCA1 mutations from serous carcinomas (7 out of 58 patients; 12.1%) and with lower frequency from endometrioid carcinomas (1 out of 14 patients; 7.1%). This evidence concerns the gene BRCA1 and endometrioid adenocarcinoma.